KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Non-Current Assets (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Other Non-Current Assets data on record, last reported at $166.0 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 37.95% year-over-year to $166.0 million; the TTM value through Sep 2025 reached $166.0 million, up 37.95%, while the annual FY2024 figure was $127.3 million, 20.89% up from the prior year.
  • Other Non-Current Assets reached $166.0 million in Q3 2025 per IONS's latest filing, up from $132.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $166.0 million in Q3 2025 and bottomed at $49.0 million in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $92.0 million, with a median of $86.0 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: rose 6.72% in 2022, then soared 75.12% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $70.6 million in 2021, then rose by 6.72% to $75.3 million in 2022, then surged by 39.73% to $105.3 million in 2023, then increased by 20.89% to $127.3 million in 2024, then skyrocketed by 30.41% to $166.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $166.0 million in Q3 2025, $132.1 million in Q2 2025, and $131.8 million in Q1 2025.